Bausch and Lomb

News

Bausch + Lomb dips on rumour of failing takeover talks

Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.

News

Bausch + Lomb buys US rights to Stada's Lucentis biosimilar

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks